Galapagos NV (GLPGF)
OTCMKTS · Delayed Price · Currency is USD
33.45
0.00 (0.00%)
Aug 26, 2025, 8:00 PM EDT
Galapagos NV Revenue
Galapagos NV had revenue of 65.29M EUR in the quarter ending June 30, 2025, a decrease of -16.16%. This brings the company's revenue in the last twelve months to 275.61M, up 5.43% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
275.61M EUR
Revenue Growth
+5.43%
P/S Ratio
6.68
Revenue / Employee
391.49K EUR
Employees
704
Market Cap
2.16B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 105.45M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Galapagos NV News
- 2 months ago - Galapagos appoints Aaron Cox as CFO - Seeking Alpha
- 2 months ago - Galapagos Appoints Aaron Cox as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 - GlobeNewsWire
- 2 months ago - Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL - GlobeNewsWire
- 3 months ago - Galapagos Creates New Subscription Right Plan - GlobeNewsWire
- 3 months ago - Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes - GlobeNewsWire
- 4 months ago - Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101 - Seeking Alpha
- 4 months ago - Galapagos NV outlines plans for pivotal CAR-T trials and SpinCo separation in 2025 - Seeking Alpha